Erratum: Cell fate regulation by gelsolin in human gynecologic cancers (Proceedings of the National Academy of Sciences of the United States of America (2014) 111 (14442-14447) DOI: 10.1073/pnas.1401166111);Cell fate regulation by gelsolin in human gynecologic cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 40, 2014, Pages 14442-14447

  Abedini, Mohammad R ^a,b,c   Wang, Pei Wen ^d   Huang, Yu Fang ^d   Cao, Mingju ^a,b   Chou, Cheng Yang ^d   Shieh, Dar Bin ^d,e   Tsang, Benjamin K ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cervical cancer; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLICE INHIBITORY PROTEIN; GELSOLIN; ITCH PROTEIN, HUMAN; PROTEIN BINDING; REPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; BIOLOGICAL MODEL; CONFOCAL MICROSCOPY; CYSTADENOCARCINOMA; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GELSOLIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROSCOPY, CONFOCAL; MIDDLE AGED; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN BINDING; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; UBIQUITIN-PROTEIN LIGASES;

EID: 84907828088     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1421407111     Document Type: Erratum

References (27)

1. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478(1-2):23-43.
2. Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5(1):26-35.
3. Ledermann JA, Kristeleit RS (2010) Optimal treatment for relapsing ovarian cancer. Ann Oncol 21 (Suppl 7):vii218-vii222.
4. Sehouli J, Alfaro V, Gonzalez-Martin A (2012) Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: Current evidence and future perspectives. Ann Oncol 23(3):556-562.
5. Cheng JQ, et al. (2002) Role of X-linked inhibitor of apoptosis protein in chemo-resistance in ovarian cancer: Possible involvement of the phosphoinositide-3 kinase/ Akt pathway. Drug Resist Updat 5(3-4):131-146.
6. Fraser M, Bai T, Tsang BK (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122(3):534-546.
7. Abedini MR, Qiu Q, Yan X, Tsang BK (2004) Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23(42):6997-7004.
8. Fraser M, et al. (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63(21):7081-7088.
9. Sasaki H, Sheng Y, Kotsuji F, Tsang BK (2000) Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60(20):5659-5666.
10. Sun HQ, Yamamoto M, Mejillano M, Yin HL (1999) Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 274(47):33179-33182.
11. Silacci P, et al. (2004) Gelsolin superfamily proteins: Key regulators of cellular functions. Cell Mol Life Sci 61 (19-20):2614-2623.
12. Tanaka H, et al. (2006) siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118(7):1680 - 1691.
13. Rahman M, Miyamoto H, Chang C (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 10(7):2208-2219.
14. Mielnicki LM, Ying AM, Head KL, Asch HL, Asch BB (1999) Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res 249(1):161-176.
15. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK (2010) Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29(1):11 -25.
16. Abedini MR, et al. (2008) Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 68(12):4511-4517.
17. Kothakota S, et al. (1997) Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278(5336):294-298.
18. Koya RC, et al. (2000) Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem 275(20):15343-15349.
19. Kusano H, et al. (2000) Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 19(42):4807-4814.
20. Shieh DB, et al. (1999) Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: The role of gelsolin expression. Cancer 85(1):47-57.
21. Shieh DB, et al. (2006) Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 42(6):599-606.
22. Rao J, et al. (2002) Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 95(6):1247-1257.
23. Bookman MA (1999) Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy. Oncologist 4(2):87-94.
24. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I (2013) Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 86(2):161-175.
25. Katsumata N, et al.; Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331-1338.
26. Markman M, et al. (2009) Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 114(2):195-198.
27. Li Q, et al. (2009) Gelsolin, but not its cleavage, is required for TNF-induced ROS generation and apoptosis in MCF-7 cells. Biochern Biophys Res Commun 385(2):284-289.